Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ADCT · NYSE · Pharmaceutical Preparations
Adc Therapeutics (ADCT) · oqro.io/stocks/ADCT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.28−0.02 (−1.54%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 13, 2026
Prosight Management, LP cut its ADCT stake below 5% (0.3%)Source5%+ stake · Stake as of Oct 22, 2026 · Filed Oct 29, 2026
Bain Capital Life Sciences Opportunities IV, L.P. now owns 10.0% of ADCT as a passive investorSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Eventide Asset Management, LLC no longer reported ADCT for Q2 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Eventide Asset Management, LLC disclosed an increased position in ADCT for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Orbimed Advisors LLC disclosed a reduced position in ADCT for Q1 2026SourceInsider trade · Traded Apr 2, 2026 · Filed Apr 3, 2026
10% owner sold ~$8.64M of ADCT shares in the open marketSourceInsider trade · Traded Apr 2, 2026 · Filed Apr 3, 2026
10% owner sold ~$8.29M of ADCT shares in the open marketSourceInsider trade · Traded Mar 31, 2026 · Filed Apr 3, 2026
10% owner sold ~$736K of ADCT shares in the open marketSourceInsider trade · Traded Mar 31, 2026 · Filed Apr 3, 2026
10% owner sold ~$707K of ADCT shares in the open marketSourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Orbimed Advisors LLC disclosed a reduced position in ADCT for Q4 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Orbimed Advisors LLC disclosed a reduced position in ADCT for Q2 2025SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Orbimed Advisors LLC disclosed an increased position in ADCT for Q4 2024SourceInsider trade · Traded Dec 11, 2024 · Filed Dec 14, 2024
10% owner purchased ~$191K of ADCT shares in the open marketSourceInsider trade · Traded Dec 11, 2024 · Filed Dec 14, 2024
10% owner purchased ~$191K of ADCT shares in the open marketSourceInsider trade · Traded Dec 11, 2024 · Filed Dec 14, 2024
10% owner purchased ~$114K of ADCT shares in the open marketSourceInsider trade · Traded Dec 11, 2024 · Filed Dec 14, 2024
10% owner purchased ~$114K of ADCT shares in the open marketSourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Orbimed Advisors LLC disclosed an increased position in ADCT for Q3 2024SourceInsider trade · Traded Apr 1, 2026 · Filed Apr 3, 2026
10% owner sold ~$643K of ADCT shares in the open marketSourceInsider trade · Traded Apr 1, 2026 · Filed Apr 3, 2026
10% owner sold ~$617K of ADCT shares in the open marketSourceInsider trade · Traded Dec 4, 2024 · Filed Dec 7, 2024
10% owner sold ~$52K of ADCT shares in the open marketSource